International Journal of Clinical Oncology

, Volume 2, Issue 2, pp 129–132 | Cite as

Changes of peripheral blood lymphocyte subsets in a long-term survivor with advanced renal cell carcinoma

  • Koji Yoshimura
  • Tamio Yamauchi
  • Hiroshi Maeda
  • Tsuneo Kawai
Case Report


We present the case of an 11-year survivor with advanced renal cell carcinoma (T4N2M1). This patient received long-term interferon-alpha (IFN-α)-based immunotherapy. Measurement of peripheral blood lymphocyte subsets suggested that reduction of the IFN-α dose might be associated with a marked increase of cytotoxic T cells, suppressor T cells, activated suppressor/cytotoxic T cells, and natural killer cells among the peripheral blood lymphocytes.

Key words

renal cell carcinoma immunotherapy interferon-alpha peripheral blood lymphocyte subsets 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Horoszewicz JS, Murphy GP. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989;142:1173–1180.PubMedGoogle Scholar
  2. 2.
    Williams RD. Immunotherapy of advanced renal cancer. Eur Urol 1990; 18 (suppl 2): 46–47.PubMedGoogle Scholar
  3. 3.
    Kobayashi Y, Yuzawa M, Sugaya Y, Kikuchi T, Morita T, Tokue A. Changes of lymphocyte subpopulation in advanced renal cell carcinoma patients with marked response to α-interferon therapy. Jpn J Urol 1994;85:1380–1387.Google Scholar
  4. 4.
    Saitoh H, Takahashi N, Suzuki T, Kogawa T, Miura H. Interferon (IFN) therapy of renal cell carcinoma patients and changes of peripheral blood lymphocyte subsets. J Jpn Soc Cancer Ther 1995;30:956–966.Google Scholar
  5. 5.
    von Rohr A, Ghosh, AK, Thatcher N, Stern PL. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 1993;67:163–171.Google Scholar
  6. 6.
    Brunda MJ, Tarnowski D, Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer 1986;37:787–793.PubMedGoogle Scholar
  7. 7.
    Sone S, Utsugi T, Nii A, Ogura, T. Differential effects of recombinant interferons α, β, and γ on induction of human lymphokine (IL-2)-activated killer activity. J Natl Cancer Inst 1988;80:425–431.PubMedGoogle Scholar
  8. 8.
    Tokuda Y, Ebina N, Golub SH. The inhibitory effect of human interferon on the generation of lymphokine-activated killer activity. Cancer Immunol Immunother 1989;30:205–212.PubMedCrossRefGoogle Scholar
  9. 9.
    Golub SH, Dorey F, Hara D, Morton DL, Burk MW. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population. J Natl Cancer Inst 1982;68:703–710.PubMedGoogle Scholar
  10. 10.
    Maluish AE, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt T, Strong DM, Weirnik P, Oldham RK, Herberman RB. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J. Immunol 1983;131:503–507.PubMedGoogle Scholar
  11. 11.
    Onishi T, Machida T, Masuda F, Hatano T, Shirakawa H, Natori T, Hamamoto M, Matsuoka Y. Assessment of tumour-infiltrating lymphocytes, regional lymph node lymphocytes and peripheral blood lymphocytes and their reaction to interferon-gamma in patients with renal carcinoma. Br J Urol 1991;67:459–466.PubMedCrossRefGoogle Scholar
  12. 12.
    Atzpodien J, Kirchner H, Korfer, A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I, Grosse J, Poliwoda H. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-α-2. Tumor Biol 1993;14:354–359.CrossRefGoogle Scholar
  13. 13.
    Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Immunological effects of treatment with sequential administration of recombinant interferon γ and α phase I trial. Cancer Res 1992;52:851–856.PubMedGoogle Scholar
  14. 14.
    Kimura M, Koida T. Changes of lymphocyte subsets with post-operative chemotherapy for breast carcinoma—a study using two color analysis. Jpn J Cancer Chemother 1989;16:2621–2625.Google Scholar
  15. 15.
    Watanabe Y, Shimizu J, Hashizume Y, Tsunamura, Y, Yamada T, Iwa T, Sakai S, Murayama, T, Koshimura S, Saito M. Changes in immunological parameters in lung cancer patients undergoing immunotherapy with streptococcal preparation OK-432. Biother 1990;2:235–245.CrossRefGoogle Scholar
  16. 16.
    Turk JL, Parker D. Effect of cyclophosphamide on immunological control mechanism. Immunol Rev 1982;65:99–113.PubMedCrossRefGoogle Scholar
  17. 17.
    Tsukagoshi S. A new antitumor drug with immunomodulating activity, Ubenimex (Bestatin). Jpn J Cancer Chemother 1987;14:2385–2391.Google Scholar
  18. 18.
    Connolly KM, Diasio RB, Armstrong RD, Kaplan AM. Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluoruridine compared to 5-fluorouracil and 5-fluoruridine. Cancer Res 1983;43:2529–2535.PubMedGoogle Scholar

Copyright information

© JSCO/CLJ 1997

Authors and Affiliations

  • Koji Yoshimura
    • 1
  • Tamio Yamauchi
    • 1
  • Hiroshi Maeda
    • 1
  • Tsuneo Kawai
    • 1
  1. 1.Department of UrologyCancer Institute HospitalTokyoJapan

Personalised recommendations